Focused Ultrasound-mediated Blood-Brain Barrier Opening for Diffuse Midline Glioma Radiosensitisation
Publication date
2024-03-19
Authors
Hart, Elvin 't
Editors
Advisors
Hoving, E.W.
Vuurden, D.G. van
Ries, M.G.
Supervisors
Document Type
Dissertation
Metadata
Show full item recordCollections
License
Abstract
Diffuse midline glioma (DMG), previously known as diffuse intrinsic pontine glioma when located in the pontine area, is a very aggressive paediatric brain tumour. After diagnosis, children with pontine DMG have a poor prognosis with a median survival of 11 months and a mortality rate of 95% within two years. Due to the location and invasive growth of the tumour, is DMG difficult to treat. Surgery is practically impossible, chemotherapy is limited due to the blood-brain barrier (BBB) and radiotherapy, which it is still the current treatment option, is restricted by severe side-effects and radio resistance occurrence. Microbubble and focused ultrasound-mediated BBB opening (FUS-BBBO) has made drug delivery into the brain parenchyma and potentially the tumour possible. Drug delivery of radiosensitisers, compounds that render tumour cells sensitive to radiation, by FUS-BBBO in combination with radiotherapy can have a beneficial effect for the patients. Although radiosensitization seems be a promising method for the treatment of DMG, there is no conclusive evidence regarding its effectiveness. The goal of this thesis was to validate the treatment effectiveness of radiosensitization through FUS-BBBO-mediated drug delivery in a DMG patient-derived xenograft (PDX) mouse model.
Keywords
Diffuse Midline Glioma; Focused Ultrasound; Radiosensitiser; Drug delivery; Blood-Brain Barrier; Mouse model; Radiotherapy; PARP